Blog

“Public Enemy No. 1 – Innovation” by Dr. Sebastian Heinz Lifts the Curtain on Why Breakthrough Technologies Stall-and What Must Be Done

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / In a bold and uncompromising address at the Future of Batteries (FOB) Summit 2025, Dr. Sebastian Heinz, CEO of High Performance Battery (HPB), launched his highly anticipated and sharply provocative new book, Public Enemy No. 1 – Innovation.

The book, now available in both English and German, delivers a blistering critique of the forces that actively block innovation in the energy sector and beyond-from entrenched politics to corporate inertia and misguided subsidies. Part memoir, part survival guide, and entirely unflinching, Public Enemy No. 1 is poised to become essential reading for policymakers, investors, founders, and scientists determined to drive progress in the energy transition.

“There is no shortage of brilliant ideas,” said Heinz from the main stage at FOB. “What’s missing is the structural integrity-the operating system-that allows these ideas to scale, survive, and ultimately succeed. This book maps both the obstacles and the exits.”

A Field Guide to the Real Innovation Battlefield

Based on Heinz’s 12-year journey scaling HPB from lab concept to industrial breakthrough, the book blends gritty first-hand experience with sweeping insights on:

• Why “Greed Eats Brains”

• How “Subsidies Go to the Wrong People”

• Why “Friendship Ends With Money”

• And when “The Burn Rate Becomes the Business Plan”

Each chapter is designed as a standalone essay-short, searing, and actionable-making it a pragmatic read for leaders who are done with PowerPoints and press releases, and ready to confront reality.

Timing the Message with a Global Battery Boom

The release couldn’t be timelier. According to Rho Motion, global battery storage installations jumped 53% in 2024, totaling 205 GWh, with North America contributing nearly 40 GWh. SolarPower Europe recently reported that the global solid-state battery market, valued at $98.96 million in 2024, is forecasted to reach $1.36 billion by 2032, expanding at a CAGR of 41.61%.

Despite this growth, Heinz warns: “The real bottleneck isn’t science-it’s the system. And if we don’t fix the system, we’ll watch innovation die in boardrooms, not labs.”

A Wake-Up Call for a Stalled System

The book’s themes align directly with the FOB Summit’s 2025 agenda: “Bridging Innovation: Bringing European Excellence to American Production. “Public Enemy No. 1 – Innovation reframes the conversation around energy transition-not just as a technical challenge, but as an organizational and political one.

Now available in print and online:

Amazon – Public Enemy No. 1 – Innovation

About the Author

Dr. Sebastian Heinz is the CEO and founding member of High Performance Battery Technology GmbH and High Performance Battery Holding AG. A recognized pioneer in sustainable energy storage, Heinz also leads the Institute for Innovation and Cooperation Management (InCoom). His work at the intersection of technology, business model innovation, and policy reform has influenced smart metering, battery systems, and platform-based models for the energy sector.

About High Performance Battery (HPB)

HPB is a European-based battery innovation company redefining solid-state energy storage for scalable, sustainable deployment. With a focus on safety, longevity, and full-cycle sustainability, HPB’s solutions are powering the future of mobility, grid storage, and industrial electrification.

Media Contact:

Monica Brennan
Head of Communications, New to The Street
Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / Uncorrelated Capital, a new alternative asset investment firm focused on litigation finance and other uncorrelated investment strategies, closed $53 million in funding from a leading private credit fund and one of the nation’s premier plaintiff law firms.

“Litigation finance is one of the most exciting asset classes in the world,” founder Miles Cole said. “We align incentives by investing alongside law firms as partners, rather than lending to them, to drive better outcomes for plaintiffs.”

Uncorrelated is investing in uncorrelated opportunities and has already deployed tens of millions of dollars into thousands of legal claims, including high-profile litigations such as Camp Lejeune.

“Coming from the technology industry, I was shocked by how little software had touched litigation finance,” added Cole. “We’re building the tooling, systems, and infrastructure to further modernize this asset class. Litigation is just the beginning.”

About Uncorrelated Capital

Uncorrelated Capital is an alternative asset investment firm focused on building long-term investments in the world’s most uncorrelated return streams, beginning with litigation finance. The firm partners with leading plaintiff-side law firms to invest in legal claims where outcomes can be improved through better alignment of incentives and long-term capital. Uncorrelated’s broader investment thesis targets niche, uncorrelated opportunities that largely behave independently of a variety of factors including interest rates, equity markets, or macroeconomic cycles, offering exposure to true alternative return streams.

Founded by Miles Cole, a serial entrepreneur who previously founded two venture-backed companies in the medical robotics and fintech sectors, Uncorrelated approaches litigation finance with a long-term, partnership-oriented focus built on alignment of incentives.

Leveraging Cole’s background in technology and venture capital, the firm plans to apply a data-driven, software-first strategy to a sector that has historically been underserved by technology.

To Learn More: Visit www.uncorrelated.capital or email info@uncorrelated.capital.

Media Contact: media@uncorrelated.capital.

SOURCE: Uncorrelated Capital

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / July 30, 2025 / Safe & Green Holdings Corp. (NASDAQ:SGBX) (“Safe & Green” or the “Company”), a leading developer of modular structures, today announced that it has restructured its previously announced private placement with D. Boral Capital, originally dated April 14, 2025. The revised terms eliminate both the Series A and Series B Common Stock Warrants, significantly reducing potential dilution and addressing the concerns raised by the NASDAQ Hearings Panel.

As a result of the restructuring:

• The Series A Warrants, originally exercisable at $0.784 per share for five years, have been cancelled.

• The Series B Warrants, originally exercisable at $0.98 per share for 30 months, have also been cancelled.

• Overall, the potential dilution to shareholders has been reduced by approximately 70%.

This restructuring conforms with the requirements of the NASDAQ Hearings Panel, which had raised a public interest concern related to the original structure of the transaction. By working closely with NASDAQ and restructuring the deal in a manner that supports both regulatory compliance and investor interests, the Company remains focused on gaining full compliance with NASDAQ listing standards.

“We acted decisively to restructure the financing in a way that better aligns with shareholder interests and ensures full compliance with NASDAQ’s listing standards,” said Mike Mclaren, Chairman and CEO of Safe & Green Holdings. “This is an important step as we continue building long-term shareholder value with a disciplined approach to capital markets activity.”

The Company originally announced the $8.0 million private placement in April 2025, with each Common Unit consisting of one share (or pre-funded warrant), one Series A warrant, and one Series B warrant. With the restructuring, the Common Stock or Pre-Funded Warrants remain in place, while both classes of dilutive warrants have been removed and exchanged for an aggregate of 60,000 shares of Series B Preferred Stock

The Company will continue to evaluate strategic opportunities while remaining focused on responsible governance and disciplined capital management.

About Safe and Green Holdings

Safe & Green Holdings Corp., a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various industries. The firm supports third-party and in-house developers, architects, builders, and owners in achieving faster execution, greener construction, and buildings of higher value. For more information, visit www.safeandgreenholdings.com and follow us at @SGHcorp on Twitter.

Safe Harbor Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the restructuring of the Company’s private placement with D. Boral Capital. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For investor and media inquiries, please contact:
investors@safeandgreenholdings.com

SOURCE: Safe & Green Holdings Corp

View the original press release on ACCESS Newswire

JACKSONVILLE, FL / ACCESS Newswire / July 30, 2025 / FRP Holdings, Inc. (NASDAQ:FRPH) anticipates issuing its second quarter earnings results on Wednesday, August 6, 2025. The Company will host a conference call on Thursday, August 7, 2025, at 9:00 a.m. (EDT). Analysts, stockholders and other interested parties may access the teleconference live by calling 1-800-343-4849 (passcode 83364) within the United States. International callers may dial 1-203-518-9848 (passcode 83364). Audio replay will be available until August 21, 2025, by dialing 1-800-839-2385 within the United States. International callers may dial 1-402-220-7203. No passcode needed. An audio replay will also be available on the Company’s investor relations page (https://www.frpdev.com/investor-relations/) following the call.

FRP Holdings, Inc. is a holding company engaged in the real estate business, namely (i) leasing and management of commercial properties owned by the Company, (ii) leasing and management of mining royalty land owned by the Company, (iii) real property acquisition, entitlement, development and construction primarily for apartment, retail, warehouse, and office, (iv) leasing and management of residential apartment buildings.

Investors are cautioned that any statements in this press release which relate to the future are, by their nature, subject to risks and uncertainties that could cause actual results and events to differ materially from those indicated in such forward-looking statements. These include, but are not limited to: the possibility that we may be unable to find appropriate investment opportunities; levels of construction activity in the markets served by our mining properties; demand for flexible warehouse/office facilities in the Baltimore-Washington-Northern Virginia area; demand for apartments in Washington D.C. and Greenville, South Carolina; our ability to obtain zoning and entitlements necessary for property development; the impact of lending and capital market conditions on our liquidity; our ability to finance projects or repay our debt; general real estate investment and development risks; vacancies in our properties; risks associated with developing and managing properties in partnership with others; competition; our ability to renew leases or re-lease spaces as leases expire; illiquidity of real estate investments; bankruptcy or defaults of tenants; the impact of restrictions imposed by our credit facility; the level and volatility of interest rates; environmental liabilities; inflation risks; cybersecurity risks; as well as other risks listed from time to time in our SEC filings; including but not limited to; our annual and quarterly reports. We have no obligation to revise or update any forward-looking statements, other than as imposed by law, as a result of future events or new information. Readers are cautioned not to place undue reliance on such forward-looking statements.

200 W. Forsyth Street, 7th Floor, Jacksonville, FL 32202

Contact:

Matthew C. McNulty
Chief Financial Officer
(904) 858-9100

SOURCE: FRP Holdings, Inc.

View the original press release on ACCESS Newswire

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center

FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (“PeriNess”), has entered into a Clinical Study Agreement (the “Agreement”) to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma.

Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Tel Aviv Sourasky Medical Center (“Sourasky Center”), will act as the principal investigator of the study.

The primary objective of this study is to explore the safety and tolerability of DNase I in combination with anti-CD19 CAR T therapy in subjects with stable or progressive large B-cell lymphoma when DNase I is given in an adjuvant setting. Secondary objectives include efficacy to be evaluated by the measure of complete response rate post CAR T infusion, duration of response and overall survival. The study has the potential for a strong translational component with a complex assessment of biomarker response and analysis of anti-CD19 CAR T expansion and persistence.

“Our data suggests that the degradation of Neutrophil Extracellular Traps (NETs) by DNase I plays a crucial role in maintaining CAR T-cell function and preventing premature CAR T-cell exhaustion. Our preclinical studies conducted show that co-administration of DNase I with anti-CD19 CAR T cells significantly reduce tumor burden, delay tumor relapse and substantially prolong survival compared to the anti-CD19 CAR T cell monotherapy groups in various syngeneic and xenogeneic experimental models of lymphoma and leukemia,” stated Alexey Stepanov, PhD, Institute Investigator at the Scripps Research Institute, and a member of Xenetic’s Scientific Steering Committee.

“Progression of large B cell lymphoma (LBCL) is the major obstacle for the success of CAR T therapies, with approximately 40-60% of the patients relapsing in the first year, and 25-35% within 3 months after CAR T infusion, depending on the CAR T product used. While patients with partial or complete response before CAR T infusion have a 1-year progression free survival of 60-80%, those with stable or progressive disease at the time of CAR T infusion have a 1-year progression free survival of 20-30%. NETs facilitate several hallmarks of cancer biology at various stages, including progression, invasion, metastasis, immunosuppression, immune escape, and resistance to therapy. A high content of NETs in lymphoma tissue and blood of patients was associated with a negative outcome. The goal of this clinical study is to improve clinical response by administering DNase I to abrogate the negative effects of NETs on the performance of immune system and CAR T cells,” added Dr. Ram.

James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic concluded, “We are pleased with the continued progress of our DNase I program and the expansion of its development in another exploratory study to further evaluate its potential in various oncology indications. We look forward to garnering additional data to realize the full potential of DNase I.”

As previously announced, in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator-initiated studies of recombinant DNase I as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company’s DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company’s website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, and other words of similar meaning, including, but not limited to, all statements regarding expectations with respect to the Clinical Trial Services Agreement with PeriNess, including statements regarding the proposed investigator-initiated study under such agreement to support an exploratory clinical study of our systemic DNase I candidate in patients with large B-cell lymphoma and the expected objectives and goal of such study, and all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our overall development strategy, the progress of our DNase I program, our expectations regarding further expansion of our body of clinical data, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) the relevance of, or our ability to utilize, the data, if any, from any investigator-initiated exploratory study, (2) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (3) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (4) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (5) failure to realize the anticipated potential of the DNase technologies; (6) the ability of the Company to obtain funding and implement its business strategy; and (7) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union.

NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs.

Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval^[1].

The Company also plans to explore a “Fast Track” designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval.

Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later.

Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children.

There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date.

Canada is having a much worse Measles season than the USA, with more than 3,800 cases^[2] to date in 2025.

A Measles holiday warning has been issued in the UK this year^[3]. England itself had more than 3,000 cases of Measles in 2024.

In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children’s Fund (UNICEF)^[4] .

Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO^[5].

A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity (“herd immunity”). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue.

While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine^[6].

Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus.

Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others.

We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire

SIOUX FALLS, SD / ACCESS Newswire / July 30, 2025 / The South Dakota Department of Health in partnership with Avel eCare, a national leader in innovative telemedicine solutions, is proud to introduce a new and uniquely impactful continuing education (CE) credit opportunity for emergency medical services professionals. Beginning August 25, EMS personnel who engage Avel for a telemedicine encounter will be eligible to earn CE credit – marking a first in virtual care.

This CE program has been approved by the South Dakota Board of Medical and Osteopathic Examiners. While the initial rollout is within South Dakota, Avel eCare intends to bring this innovative model to additional states and EMS systems across the country.

“This is more than a new offering, it’s a national first,” said Melissa Magstadt, Secretary of South Dakota Department of Health. “We’re not just improving care in the moment. We’re advancing the careers of EMS professionals, enhancing agency operations, and creating a full-circle support system that sets Avel apart.”

With this model, CE credit is earned in the field, not in a classroom. EMS teams continue to provide patient care while gaining access to expert guidance from Avel’s emergency physicians, paramedics, and nurses. A clinical debrief following the encounter reinforces decision-making and strengthens learning, making education an integrated part of every call.

While this program marks a major innovation, it also addresses a critical challenge in rural EMS: workforce turnover and training fatigue. EMTs and paramedics-many of them volunteers-juggle unpredictable call schedules, demanding clinical responsibilities, and state-mandated continuing education requirements. Traditionally, earning CE credits has meant additional time away from work or family, creating a strain on already overextended teams.

“Our board-certified physicians and experienced paramedics are delivering real-time clinical guidance and now, real-time professional development, all while helping providers stay hands-on with their patients” said Dr. Tyler Price, Medical Director at Avel eCare. “It validates what we’ve known all along – that our virtual interactions aren’t just helpful, they’re educational. We’re training and supporting EMS professionals in real time, with no disruption to the care they’re delivering.”

Through this real-time educational model, EMS personnel gain critical knowledge and confidence while in the field. Clinical support delivered in the back of the ambulance, followed by a brief debrief, reinforces learning in the context of real patient care.

“Avel’s model is not just about connecting clinicians through a screen,” concluded Doug Duskin, CEO of Avel eCare. “It’s about empowering communities with access to the highest level of medical care. And now, we’re extending that impact by offering accredited education, reinforcing our commitment to providers and patients alike.”

About Avel eCare
Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

Media Contact:
Jessica Gaikowski
Avel eCare
media@avelecare.com

SOURCE: Avel eCare

View the original press release on ACCESS Newswire

Global live streaming viewership grew 5% year-over-year to 9.1 billion hours watched during 2025 Q2, reflecting the highest quarterly level since 2021

FRISCO, TEXAS / ACCESS Newswire / July 30, 2025 / Stream Hatchet, the leading provider of data analytics for the live streaming and gaming ecosystem and wholly-owned subsidiary of GameSquare Holdings (NASDAQ:GAME), (“GameSquare”, or the “Company”), has released its Q2 2025 Live Streaming Trends Report. The report reveals key insights into the evolution of the global live streaming market across gaming, esports, and entertainment.

Access to the report is available at: https://www.streamhatchet.com/reports/q2-2025-live-streaming-trends

“The Q2 2025 report from Stream Hatchet underscores the continued growth of live streaming as a dominant force in media consumption,” said Justin Kenna, CEO of GameSquare. “These insights highlight how audiences are shifting toward interactive, creator-led content experiences that offer greater engagement than traditional formats.”

Key Insights from Stream Hatchet’s 2025 Q2 Report:

1. 9.1 billion hours watched in 2025 Q2, reflecting the highest quarterly level since 2021

   • Live streaming viewership continues to grow, up 5% year-on-year, surpassing the 9 billion mark for the first time since 2021

2. YouTube Gaming recorded its highest ever quarterly viewership at 2.2 billion hours watched

   • Twitch’s market share continues to decline, down 4.6% in 2025 Q2 to 54%

   • YouTube Gaming holds onto just under a quarter of the market share

   • Kick continues to grow, with their market share up 5.5% to almost 11% of the streaming market

3. Despite 37% fewer tournaments compared to 2024 Q2, esports tournaments recorded a 6% increase in viewership to 729 million hours watched

   • Viewership was evenly split between co-streaming channels and official esports channels, highlighting audiences growing preference for creator-driven content

For more information on Stream Hatchet and insight into the esports and streaming markets, please visit their website at www.streamhatchet.com.

About GameSquare Holdings, Inc.

GameSquare (NASDAQ: GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. Complementing our operating strategy, GameSquare operates a blockchain-native Ethereum treasury management program designed to generate onchain yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.

To learn more, visit www.gamesquare.com.

About Stream Hatchet

Stream Hatchet delivers real-time, actionable insights into the gaming and live-streaming ecosystem across 16 platforms. From performance benchmarking to campaign ROI and influencer intelligence, Stream Hatchet empowers game publishers, brands, agencies, and tournament organizers with the industry’s most granular data and reporting tools.

For more information visit www.streamhatchet.com .

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company’s future performance, revenue, growth and profitability; and the performance of the live streaming market . These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company’s ability to grow their business and being able to execute on their business plans, the Company being able to complete and successfully integrate acquisitions, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company’s ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company’s portfolio across entertainment and media platforms, dependence on the Company’s key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company’s most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Corporate Contact
Lou Schwartz, President
Phone: (216) 464-6400
Email: ir@gamesquare.com

Investor Relations
Andrew Berger
Phone: (216) 464-6400
Email: ir@gamesquare.com

Media Relations
Chelsey Northern / The Untold
Phone: (254) 855-4028
Email: pr@gamesquare.com

SOURCE: GameSquare Holdings, Inc.

View the original press release on ACCESS Newswire

With IRS tightening enforcement on dependents and tax credits, families face heightened scrutiny for mistakes on 2024 and 2025 returns

IRVINE, CA / ACCESS Newswire / July 30, 2025 / As the IRS ramps up enforcement in the wake of pandemic-era tax benefits and evolving digital filing tools, parents are being warned that mistakenly claiming the Child Tax Credit (CTC) – even unintentionally – could lead to audits, delayed refunds, or serious financial penalties.

Clear Start Tax, a leading tax resolution firm, is alerting taxpayers to a growing trend in IRS investigations centered around ineligible or duplicate child-related tax credit claims. With billions in credits distributed over the past few years and ongoing pressure to recover erroneous payments, experts say families should be extra cautious when preparing their tax returns – particularly when multiple households or caregivers are involved.

“The Child Tax Credit helped millions of families, but it also opened the door for confusion,” said a spokesperson for Clear Start Tax. “We’re seeing more cases where two parents each claimed the same child, or where someone claimed a dependent they’re no longer eligible for – often without realizing the full consequences.”

A Common Mistake, With Expensive Outcomes

The Child Tax Credit, which provides up to $2,000 per qualifying child, is meant to support low- and middle-income families. However, claiming the credit requires strict adherence to IRS eligibility rules, including proof of residency, relationship, and financial support. In 2025, the IRS is reportedly expanding its use of AI tools to detect inconsistencies and duplicate claims, triggering automated audits and refund delays.

For families navigating custody agreements, blended households, or informal caregiving situations, the rules can be murky – and mistakes are common.

“We’ve had clients come to us after receiving a CP75 letter from the IRS – a notice that flags their return for audit due to a claimed dependent,” said the Clear Start Tax spokesperson. “In some cases, their refund was frozen. In others, they were hit with repayment demands plus interest and penalties.”

According to IRS data, tens of thousands of families are flagged each year for dependent-related discrepancies, many stemming from unclear custody situations or outdated records. In more serious cases, repeated or fraudulent claims can even be referred for criminal investigation.

Prevention Over Penalties

While honest mistakes are not considered fraud, the IRS can still impose steep penalties if it deems a taxpayer was negligent or failed to correct known issues. In some cases, a taxpayer may be barred from claiming the credit for up to two years.

“Parents are often surprised to learn they can lose future eligibility just from one filing error,” said the Clear Start Tax spokesperson. “The best defense is proactive preparation and, if needed, professional guidance before filing.”

For those who’ve already received an IRS letter or notice related to the Child Tax Credit, Clear Start Tax advises acting quickly to avoid escalation. Responding with proper documentation within the deadline window is essential to protect refunds and avoid enforcement action.

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

About Clear Start Tax

Clear Start Tax is a nationally recognized tax resolution firm helping individuals and families navigate complex IRS issues, from audits and debt to unfiled returns and penalties. With a focus on client advocacy and long-term financial solutions, the firm has helped thousands of taxpayers achieve relief and regain peace of mind.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information
Clear Start Tax
Corporate Communications Department
tech@clearstarttax.com
(949) 800-4011

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain phases

MIAMI, FLORIDA / ACCESS Newswire / July 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical data showing that its topical Ketamir-2 cream delivered similar and consistent pain relief compared with injected morphine in a validated animal model of acute and inflammatory pain.

In the study, Ketamir-2 cream was applied topically to the affected area 30 minutes before pain was induced using the formalin model, a widely accepted preclinical method for evaluating both acute and inflammatory pain. In this model, a small amount of formalin (a dilute formaldehyde solution) is injected into the paw, producing two well-characterized phases of pain: an initial acute phase driven by direct nerve activation, followed by a prolonged inflammatory phase associated with central sensitization (a mechanism shared with neuropathic pain). Researchers monitored spontaneous pain-related behaviors-specifically paw licking and paw lifting-using AI-assisted video analysis of 5-minute slots over a 60-minute period.

Topical Ketamir-2 was effective as Injected morphine in both phases, nearly eliminating pain behaviors during the acute phase and maintaining a strong, durable effect throughout the inflammatory phase. These results indicate Ketamir-2’s potential to modulate both peripheral and central pain pathways with topical, localized delivery.

“These findings confirm Ketamir-2’s potential as a next-generation, non-opioid topical treatment for localized pain,” said Erez Aminov, Chairman and CEO of MIRA. “With our oral IND already cleared and a Phase 2a neuropathic pain trial expected to begin by year-end, this topical data meaningfully expands our clinical and commercial strategy. We’re advancing a dual-route platform that can target both systemic and localized pain conditions-offering optionality for patients and value for shareholders.”

Dual-Phase Pain Relief Without Systemic Burden

Unlike systemic analgesics, which circulate throughout the body and may cause unwanted side effects, Ketamir-2’s topical formulation is designed to provide direct, localized pain relief with minimal systemic exposure. Its performance across both acute and inflammatory pain phases supports a broad therapeutic profile-potentially applicable to conditions such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, and osteoarthritis.

“What’s remarkable is Ketamir-2’s ability to nearly abolish acute pain behavior while also suppressing inflammation-driven responses,” said Dr. Itzchak Angel, CSA at MIRA. “This dual-phase efficacy is rarely seen with topicals and strongly supports our rationale to continue advancing preclinical studies aimed at treating complex localized pain conditions.”

Addressing an $11.5 Billion U.S. Topical Pain Market

The U.S. topical pain relief market is projected to exceed $11.5 billion by 2025, driven by demand for safer, non-opioid, non-systemic options, according to a report by Research and Markets. Chronic pain affects more than 51 million adults in the U.S., and many of the most prevalent pain conditions-such as osteoarthritis and neuropathy-are localized in nature.

Ketamir-2’s topical formulation is designed to meet this need by offering:

• Fast onset of action

• Efficacy in both neurogenic and inflammatory pain

• Minimal systemic absorption

• Non-opioid, non-habit forming mechanism of action

Unlike many pain programs that pursue either systemic or localized delivery, MIRA is developing Ketamir-2 in both oral and topical forms. This dual-path approach may enable clinical evaluation across a broader spectrum of pain conditions-ranging from widespread neuropathic syndromes to localized inflammatory pain. If successful, this strategy could support differentiated product profiles and expand potential treatment opportunities.

A Scalable Non-Opioid Pain Platform

MIRA is currently conducting a Phase 1 clinical trial of oral Ketamir-2 in healthy volunteers. Following FDA clearance of its Investigational New Drug (IND) application, a Phase 2a clinical trial in neuropathic pain is expected to begin later this year in the USA.

The Company is also continuing preclinical development of the topical formulation to further characterize its pharmacological effects and support potential clinical advancement. Together, these efforts reflect a platform strategy designed to address high-burden pain conditions through both systemic and localized approaches.

“As we continue to execute on our clinical and regulatory milestones, we remain focused on unlocking the full value of the Ketamir-2 platform-either through internal advancement or strategic partnership,” added Aminov.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire